Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-05212372 · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Subjects will be assigned to receive either PF-05212372 or placebo in each period |
| Cohort 2 | EXPERIMENTAL | Subjects will be assigned to receive either PF-05212372 or placebo in each period |
| Name | Type | Description |
|---|---|---|
| PF-05212372 | DRUG | Inhaled. Dose Level 1: 50 ug |
| Placebo | DRUG | Inhaled |
Inclusion Criteria: Healthy subjects. (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests). Exclusion Criteria: * Evidence or...
PF-05212372 is an investigational small molecule being developed by Pfizer, Inc. It is currently in Phase 1 clinical development. The drug is being studied for its safety, toleration, and pharmacokinetics in healthy volunteers.
PF-05212372 is a small molecule, but its specific molecular target has not been disclosed in the available information. The drug is being evaluated in early-stage clinical trials for safety and toleration.
PF-05212372 is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE on the New York Stock Exchange.
PF-05212372 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in healthy volunteers to assess safety and pharmacokinetics.
PF-05212372 has one completed Phase 1 clinical trial, identified as NCT01415102. This was a first-in-human study conducted in Belgium to evaluate the safety, toleration, and plasma concentration of single inhaled doses of the drug in healthy people.
PF-05212372 is the primary name for this investigational drug. No alternative names have been reported in the available information.